| Factor | Score | Distribution | Value | Avg | Rank |
|---|---|---|---|---|---|
Valuation | 76 | 72.1x | 17.3x | Top tier | |
Growth | 39 | 0.8% | 7.1% | Bottom tier | |
Quality | 49 | 3.3% | 4.5% | Around median | |
Safety | 36 | 4.2x | 2.6x | Bottom tier | |
Capital Return | 26 | 0.00% | 0.06% | Bottom tier | |
Momentum | 50 | 11.6% | -1.6% | Around median | |
Sentiment | 77 | 7 | 3 | Top tier |
The floor: what the company is worth if growth stopped today
93% of today's price is what a buyer pays for growth that has not happened yet.
10-year US Treasury yield 4.96% as of 2026-10-22. Estimates computed from company data and analyst targets, not investment advice.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.
Integra LifeSciences Holdings Corporation operates in medical technologies focused on specialty surgery and tissue reconstruction. Its specialty surgery business includes neurosurgery products such as Certas Plus, CUSA, and BactiSeal, along with surgical instruments and ear, nose, and throat products, while its tissue reconstruction portfolio includes Integra Skin, PriMatrix, AmnioExcel, MicroMatrix, DuraSorb, and SurgiMend. The company leverages its relationships with hospitals, IDN networks, and GPO organizations to expand institutional contracting across this portfolio, with most of its procedures concentrated in acute care and injury treatment rather than purely elective procedures.
In fiscal Q2 2026, revenue was $418.8 million, compared with management-reported rounded revenue of $419 million, representing growth of 0.8% on a reported basis and 0.7% organically. Gross profit according to EDGAR filings was approximately $219.7 million, equivalent to an accounting gross margin of about 52.5%, while net income was $4.5 million and accounting earnings per share were $0.06; on an adjusted basis, gross margin was 61.3% versus 60.7% in fiscal Q2 2025, adjusted EBITDA margin was 18.7% versus 17.1%, and adjusted earnings per share were $0.56, up 24%.
The specialty surgery segment accounted for approximately $309.3 million, or about 74% of fiscal Q2 2026 revenue, and achieved organic growth of 1.6%. Tissue reconstruction generated $109.5 million, or approximately 26% of revenue, and declined 2% organically, with growth in DuraSorb and improvement in PriMatrix offset by a year-over-year decline in Integra Skin due to the comparison with the clearing of backorders in fiscal Q2 2025, and a decline in MicroMatrix. On a trailing-twelve-month basis in 2026, revenue was $1.6 billion and gross profit was $864.6 million, but net income remained negative at $7.2 million.
The analyst consensus is “Buy,” with an average price target of $20.5 and a range of $19 to $25; the average is approximately at the upper end of the 52-week range of $8.7–$20.49, while the highest target exceeds it. The price-to-earnings multiple does not provide a valid valuation anchor because of the trailing-twelve-month accounting loss in 2026, so achieving analysts' targets is linked to improved earnings and margins, the recovery of PriMatrix and SurgiMend sales, and the reduction of leverage from 4.1 times.
Figures in the text are as of 2026-09-02; the live price is shown at the top of the page.
Fiscal Q2 2026 revenue was approximately $418.8 million, with reported growth of 0.8% and organic growth of 0.7%. The specialty surgery segment led performance with revenue of $309.3 million and organic growth of 1.6%, supported by Certas Plus, CUSA, and BactiSeal products and improved supply availability. In contrast, tissue reconstruction declined 2% organically to $109.5 million, but adjusted earnings per share rose 24% to $0.56 and adjusted EBITDA margin increased to 18.7%.
Integra restarted manufacturing at the Braintree facility and is building inventory for a phased and disciplined launch of SurgiMend 510(k) in fiscal Q4 2026. Fiscal 2026 guidance does not include a material contribution from the product because customer and share recovery is expected to extend over several quarters. Management indicated a modest recovery that could reach approximately 50% of its historical performance of $40 million, with the launch beginning among its largest historical users and clinical opinion leaders.
Automated analysis for informational purposes only — not investment advice.
The company expects organic revenue growth of between 0.8% and 3.3% during fiscal 2026 and reported revenue of between $1.654 billion and $1.695 billion after updating the foreign-exchange impact. The adjusted earnings per share range is between $2.40 and $2.50, with targeted expansion of approximately 60 basis points in adjusted gross margin and 100 basis points in adjusted EBITDA margin compared with fiscal 2025. For fiscal Q3 2026, it expects revenue of between $410 million and $425 million and adjusted earnings per share of between $0.53 and $0.61.
Net debt was $1.6 billion on June 30, 2026, and gross leverage declined to 4.1 times from 4.5 times at the end of fiscal 2025. The company had total liquidity of approximately $496 million, including approximately $274 million in cash and short-term investments, and generated operating cash flow of $22.8 million in fiscal Q2 2026. Management is targeting an approach toward the upper end of the 2.5–3.5 times leverage range by the end of fiscal 2026, but it also expects higher interest expense if the bank debt refinancing is completed in the second half.
SurgiMend PMA approval remains contingent on a successful FDA pre-approval inspection of the Braintree facility, despite the completion of the safety and efficacy review and an approvable determination. For DuraSorb, patient enrollment and follow-up have been completed and data analysis has begun, but it also requires an inspection of the manufacturing facility before approval; the company expects SurgiMend approval earlier in fiscal 2027 and DuraSorb approval later in the year. All warning letter actions are also expected to be implemented by the end of fiscal 2026, while the timing of inspections and approvals remains subject to the FDA.